Table 3.
Model’s prediction according to the presence of genetic mutation/risk and Aβ pathology in DIAN and PREVENT-AD cohorts (test set only).
| DIAN | PREVENT-AD | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mutation NonCarriers | Mutation Carriers | Mutation NonCarriers Aβ− | Mutation Carriers Aβ− | Mutation Carriers Aβ+ | APOE4 NonCarriers | APOE4 Carriers | Aβ− | Aβ+ | |
| N | 29 | 125 | 29a | 75 | 39 | 147 | 108 | 50 | 14 |
| Chronological Age in years (±SD) | 38.90 (±11.55) | 34.35b (±9.66) | 38.90 (±11.55) | 33.15b (±9.09) | 38.18b (±10.04) | 63.89 (±5.74) | 63.05 (±4.77) | 62.90 (±4.28) | 64.71 (±5.69) |
| Predicted Age in years (±SD) | 35.35 (±12.90) | 42.51b (±13.90) | 35.35 (±12.90) | 41.55b (±13.19) | 41.18b (±14.09) | 68.94 (±5.14) | 68.46 (±5.01) | 68.80 (±6.08) | 70.37 (±2.97) |
| PAD in years (±SD) | −3.54 (±18.99) | 8.19b (±17.63) | −3.54 (±18.99) | 8.40b (±17.21) | 6.62b (±18.09) | 5.04 (±7.62) | 5.41 (±6.79) | 5.90 (±7.60) | 5.66 (±6.56) |
Aβ− amyloid-negative, Aβ+ amyloid-positive, PAD predicted age difference, SD standard deviation.
aAβ-PET data was missing for 2 mutation non-carriers. To avoid further reducing the number of individuals in this group, they were both exceptionally kept for the corresponding analysis and their Aβ negativity was determined based on (i) their CSF data (available for both of them) and (ii) the unlikelihood that they have detectable Aβ pathology on PET considering their young age and the absence of ADAD mutation.
bindicates a significant difference from DIAN mutation noncarriers (p < .05); of note, no differences were found between DIAN mutation carriers Aβ− and DIAN mutation carriers Aβ+, neither in PREVENT-AD when comparing APOE4 noncarriers to APOE4 carriers or Aβ− to Aβ+. Statistical values were obtained using general linear models, including group as a predictor, without adjustment (two-sided).